Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase EARLY_PHASE1 2Phase NA 1

Status

Unknown 2Withdrawn 1

Sponsor Class

OTHER 89NIH 28INDUSTRY 7OTHER_GOV 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Interleukin-2 × Clear all
NCT03166397 2023-01-26

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Sheba Medical Center

Phase 2 Unknown
30 enrolled
Dermatologic

Melanoma

NCT03412526 2019-04-04

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Sheba Medical Center

Phase 2 Unknown
15 enrolled
Gynecologic

Ovarian Neoplasms

NCT03222089 2018-03-27

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Fujian Cancer Hospital

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡